推薦產(chǎn)品
3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole 2-(chloromethyl)-3-methylpyridinehydrochloride 1-(2-bromo-4-methylphenyl)ethanone 3-chloroisoquinoline-4-carbonitrile 5,8-dichloropyrido[3,2-d]pyridazine 2-bromomalononitrile 2-(4-(bromomethyl)phenyl)benzo[d]thiazole 1-(bromomethyl)-3-methoxy-2-nitrobenzene 6-bromo-1H-[1,2,3]triazolo[4,5-b]pyridine 4-iodo-2-((trimethylsilyloxy)methyl)thiazole 6-iodoimidazo[1,2-a]pyridine-3-carbonitrile 2-(4-chlorophenyl)-2-morpholinoacetonitrile 4-chloro-7H-pyrrolo[2,3-d]pyrimidine 4-chloroisothiazole 5-bromo-6-chloro-1H-indole 7-chloro-3H-imidazo[4,5-b]pyridine ethyl3-(4-formylphenyl)propanoate 2,3-dibromobenzaldehyde 1-(5H-chromeno[2,3-b]pyridin-7-yl)ethanone 5H-chromeno[2,3-b]pyridin-5-one 3-chloroisoquinoline-4-carbaldehyde (E)-2-(3-oxoprop-1-enyl)benzaldehyde methyl4-formyl-3-nitrobenzoate 5,6-dimethoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-one 1-methylbicyclo[4.1.0]heptan-3-one 3-nitro-4-(trifluoromethoxy)benzaldehyde 2-hydroxyquinoline-6-carbaldehyde 2-nitro-3-(trifluoromethyl)benzaldehyde 1-(2-fluoro-4-methoxyphenyl)propan-2-one tert-butyl3-fluoro-4-oxopiperidine-1-carboxylate tert-butyl3-oxopropylcarbamate 2,2-dimethylcyclohexanone 9H-carbazole-3-carbaldehyde N,N-dimethyl-2-oxoacetamide 2-methylpent-4-yn-2-ol 3-tert-butyl-4-hydroxybenzonitrile 4-bromo-2-tert-butylphenol 1,3-dibutoxypropan-2-ol methyl4-hydroxyquinoline-6-carboxylate methyl3-cyano-4-hydroxybenzoate 4-chloro-6-methoxyquinolin-7-ol 3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol 2-(2-aminothiazol-5-yl)ethanolhydrochloride (R)-ethyl2-chloropropanoate (S)-4-amino-5-(4,4-dimethylcyclohexylamino)-5-oxopentanoicacid (1s,4s)-4-hydroxycyclohexanecarboxylicacid (S)-2-(tetrahydrofuran-3-yloxy)aceticacid (1S,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol (R)-4-(hydroxymethyl)oxazolidin-2-one (S)-4-(hydroxymethyl)oxazolidin-2-one 化工資訊 6月2日，記者從佛慈制藥股份有限公司獲悉，在日前召開的甘肅省地方習(xí)用藥材質(zhì)量標(biāo)準(zhǔn)審核審定會議上，由佛慈制藥研究院承擔(dān)的甘肅省中藥材標(biāo)準(zhǔn)修訂順利通過專家組審定。
據(jù)了解，按照2020年版《甘肅省中藥材標(biāo)準(zhǔn)》修訂背景、甘肅習(xí)用藥材修訂工作進(jìn)展情況及此次修訂工作下一步要求，佛慈制藥研究院從企業(yè)自身產(chǎn)品出發(fā)，承擔(dān)了人參須等五個地方藥材標(biāo)準(zhǔn)的修訂工作，在本次審定會中進(jìn)行了匯報和答辯，與會專家對修訂方案和研究內(nèi)容進(jìn)行了認(rèn)真討論，最終順利通過審定。至此，佛慈制藥承擔(dān)的全部五個地方藥材的標(biāo)準(zhǔn)修訂工作畫上了圓滿的句號，將在2020年版《甘肅省中藥材標(biāo)準(zhǔn)》中出版、實施和推廣。
佛慈制藥作為甘肅省中藥龍頭企業(yè)積極合作，深入調(diào)研，扎實開展修訂工作。通過中藥民族藥標(biāo)準(zhǔn)化研究，對挖掘和保護(hù)甘肅道地藥材資源、繼承和弘揚(yáng)中醫(yī)藥傳統(tǒng)文化、帶動中醫(yī)藥產(chǎn)業(yè)科技創(chuàng)新、推動我省中醫(yī)藥產(chǎn)業(yè)發(fā)展、保障公眾用藥安全意義深遠(yuǎn)，具有很大的社會和經(jīng)濟(jì)效益。
